Global Measurable Residual Disease Testing Market Growth (Status and Outlook) 2025-2031

The global Measurable Residual Disease Testing market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.

Measurable residual disease (also known as “minimal residual disease”) refers to the number of cancer cells that remain during and after cancer treatment. Complete remission (less than 5% blasts in bone marrow) by morphologic assessment is not enough to accurately depict remaining malignant cells.

United States market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Measurable Residual Disease Testing is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Measurable Residual Disease Testing players cover Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Measurable Residual Disease Testing Industry Forecast” looks at past sales and reviews total world Measurable Residual Disease Testing sales in 2024, providing a comprehensive analysis by region and market sector of projected Measurable Residual Disease Testing sales for 2025 through 2031. With Measurable Residual Disease Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Measurable Residual Disease Testing industry.

This Insight Report provides a comprehensive analysis of the global Measurable Residual Disease Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Measurable Residual Disease Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Measurable Residual Disease Testing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Measurable Residual Disease Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Measurable Residual Disease Testing.

This report presents a comprehensive overview, market shares, and growth opportunities of Measurable Residual Disease Testing market by product type, application, key players and key regions and countries.

Segmentation by Type:

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Other

Segmentation by Application:

Hematological Malignancies

Leukemia

Lymphoma

Solid Tumors

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Adaptive Biotechnologies Corporation

ArcherDX, Inc. (Invitae Corporation)

Asuragen

Arup Laboratories

Bio-Rad Laboratories

Cergentis B.V.

F. Hoffmann- La Roche Ltd

Guardant Health

ICON plc

Invivoscribe

Laboratory Corporation of America Holdings

Mission Bio

Natera, Inc.

NeoGenomics Laboratories

Opko Health

Quest Diagnostics Incorporated

Sysmex Corporation

Genetron Health

Please note: The report will take approximately 2 business days to prepare and deliver.